Dendreon Presenting Today at AUA
April 28, 2009 at 8:00 am EST | Tags: Clinical Trials, Conferences
Two weeks after making history and sending its stock up 200%+, Dendreon is set to present the full PROVENGE data today at American Urological Association annual meeting. Dendreon will discuss the details of the Phase 3 IMPACT study of PROVENGE (sipuleucel-T) in men with advanced prostate cancer which met its primary endpoint of improving overall survival compared to a placebo control (i.e. equal to or greater than 22% difference).
The presentation will be at 2:20PM CST/3:20PM EST. Although there will most likely be a press release before and immediately after the presentation, Dendreon will also be hosting a webcast from the convention at 4:30PM CST, 530PM EST. Details for dialing in can be found right here.
Xconomy has also done a great take on PROVENGE and what to expect at today’s meeting.
Image from themarketguardian
![[Loading...]](http://www.iguanabio.com/wp-content/themes/IguanaBio/images/ajax-loader.gif){kind=small}
